Nirav Shah, MD

Dose expansion: The maximum tolerated dose of CAR20.19.22 cells

Mosunetuzumab

CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)

2.5 X 10^6 cells/kg

Pegfilgrastim

Cyclophosphamide

2.5x10^6 cells/kg CAR20.19.22 cells

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

+17 more interventions

25 unique interventions3 categories

Analytics

Trial Phases

Phase 16

Phase 22

Trial Status

Completed1

Recruiting3

Terminated2

Other1

Role Distribution

Principal Investigator6

Other Roles1

PI Rate86%

Activity Timeline

Clinical Trials (7)

NCT06594939Phase 2Recruiting

Diffuse Large B Cell Lymphoma (DLBCL)

StudychairStart date: 2026-06-01

NCT05990465Phase 1Recruiting

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Burkitt LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma+3 more

PrincipalinvestigatorStart date: 2025-02-06

NCT05094206Phase 1Terminated

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

B-cell Chronic Lymphocytic LeukemiaB-cell Non Hodgkin Lymphoma

PrincipalinvestigatorStart date: 2022-06-30

NCT04186520Phase 1/2Recruiting

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Central Nervous System LymphomaChronic Lymphocytic Leukemia (CLL)Diffuse Large B Cell Lymphoma+5 more

PrincipalinvestigatorStart date: 2020-05-18

NCT03588936Phase 1Terminated

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Acute LeukemiaChronic LeukemiaLymphoma+1 more

PrincipalinvestigatorStart date: 2018-09-14

NCT03019055Phase 1Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Chronic Lymphocytic LeukemiaLymphoma, B-CellLymphoma, Non-Hodgkin+1 more

PrincipalinvestigatorStart date: 2017-10-16

NCT07335328Phase 1Not Yet Recruiting

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

B-cell Non Hodgkin Lymphoma

Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Leukemia, Lymphocytic, Chronic, B-Cell3 Lymphoma, Large B-Cell, Diffuse3 Lymphoma, Non-Hodgkin3 B-cell Non Hodgkin Lymphoma2 Lymphoma, Follicular2 Lymphoma, Mantle-Cell2 Marginal Zone Lymphoma2 Acute Leukemia1

Affiliations

Medical College of Wisconsin

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

24 trials

Shared therapeutic areas:

LymphomaAcute LeukemiaLymphoma, Follicular+5 more

Worked with same sponsors:

Medical College of Wisconsin

Similarity Score16%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

17 trials

Shared therapeutic areas:

Lymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-CellB-cell Non Hodgkin Lymphoma+3 more

Similarity Score12%

Arnon Nagler, MD

Chaim Sheba Medical Center

12 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinMyelodysplastic SyndromesLeukemia, Lymphocytic, Chronic, B-Cell+2 more

Similarity Score10%

Hagop Youssoufian, MD

Verastem, Inc.

20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma+1 more

Similarity Score8%

Helen Heslop, MD

Baylor College of Medicine

17 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell+1 more

Similarity Score8%

Michael B Gill

Power Life Sciences Inc.

105 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma+1 more

Similarity Score8%

Qifa Liu

Nanfang Hospital, Southern Medical University

33 trials

Shared therapeutic areas:

Myelodysplastic SyndromesAcute LeukemiaLymphoma, Large B-Cell, Diffuse

Lymphoma, B-CellLymphomaLymphoma, Non-Hodgkin

David Cunningham

Royal Marsden NHS Foundation Trust

13 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinMyelodysplastic Syndromes

Yves Beguin, MD, PhD

CHU-ULg

7 trials

Shared therapeutic areas:

Acute LeukemiaMyelodysplastic SyndromesLymphoma, Non-Hodgkin

Project Leader

Ono Pharmaceutical Co., Ltd.

47 trials

Shared therapeutic areas: